خط مشی دسترسیدرباره ما
ثبت نامثبت نام
راهنماراهنما
فارسی
ورودورود
صفحه اصلیصفحه اصلی
جستجوی مدارک
تمام متن
منابع دیجیتالی
رکورد قبلیرکورد بعدی
نوع مدرک : TF
زبان مدرک : فارسی
شماره رکورد : 67069
شماره مدرک : ‭پ۵۳۵۴۱‬
شماره راهنما : ‭ت۲۷۲۷‬
سر شناسه : متولی حقی، نسرین سادات
عنوان اصلي : تاثیر تجویز کوتاه مدت مونته لوکاست بر بروز حمله آسم ناشی از عفونتهای با علایم کلینیکی عفونتهای تنفسی ویروسی در کودکان مبتلا به آسم متناوب
نام عام مواد : [پایان‌نامه]
نام نخستين پديدآور : /نسرین سادات متولی حقی
نام ساير پديدآوران : ؛استاد راهنما: حمید آهنچیان، فاطمه بهمنش
نام ساير پديدآوران : ؛استاد مشاور: علی جعفری، جواد سیدی، محمد خواجه دلوئی
عنوان ديگر : عنوان به انگلیسی‭Evaluation the clinical effects of short-course Montelukast on Asthma symptoms and exacerbation due to viral respiratory infection in children with intermittent Asthma :‬
وضعيت نشر : دانشگاه علوم پزشکی مشهد، ‭۱۳۹۲‬، دانشکده پزشکی
صفحه شمار : ‮‭[۷۸]‬ ص.‬: نمودار
يادداشت : چکیده فارسی، چکیده انگلیسی
يادداشت : چاپی
خلاصه يا چکيده : ‭agonist use and nights awakened , time off from school and limitation of activity . Montelukast has not important sideffect and is available. Further studies are needed with beyond cases and duration of study. Keywords: Viral upper respiratory tract infection; Childhood asthma; Montelukast ; Asthma exacerbation; placebo; Intermitent asthma -agonist usage by 17.2 (p=0.000) and doctor visits by12.2 (p=0.001), whereas there was a nonsignificant reduction in wheezing, thacypnea, respiratory distress, asthma exacerbation, prednisolone use and hospitalization than placebo.(p=0.801) Conclusion: A short course of Montelukast , introduced at the first sign of an viral URI ,results in a reduction in symptoms such as: cough,-month period.Treatment with Montelukast or placebo was initiated by parents at the onset of viral upper respiratory tract infection and continued for 7 days. Results: A total of 187 children with intermittent asthma were randomized , 93 to montelukast and 94 to placebo .Montelukast significantly decreased the cough by 6 (p=0.006), nighttime awakenings by 5.4 (p=0.013), interference with normal activity by 6 (p=0.006), time off from school by 6 (p=0.006), -controlled clinical trial over 2-blind , placebo-12 years with intermittent asthma participated in this multicenter , randomized , double-Background: Asthma is a major public health problem with a huge social and economic burden affecting 300 million people worldwide. Viral respiratory infections are the major cause of acute asthma exacerbations and may contribute to asthma inception in high risk young children with susceptible genetic background. Acute exacerbations are associated with decreased lung growth or accelerated loss of lung function and, as such, add substantially to both the cost and morbidity associated with asthma. In children, intermittent asthma is the most common pattern and is responsible for the majority of exacerbations.Leukptrienes are important inflammatory mediators in allergic and nonallergic inflammation of the entire airways.Montelukast (a leukotriene receptor antagonist) has a rapid onset of action and may be effective on reduction of asthma exacerbation if that use early onset viral upper respiratory tract infection. Method: Children, aged 6‬
 
 
 
(در صورت عدم وضوح تصویر اینجا را کلیک نمایید)